LEO Pharma strengthens global leadership team
The company has set out on an ambitious growth journey to become a leading provider of innovative medicines helping patients with skin diseases. To align with its strategic objectives, it re-organizes its executive leadership team.
Dr. Monica Shaw, M.D., will assume the position of Executive Vice President, Region Europe+, effective July 1, 2020. Shaw joins LEO Pharma from GSK/ViiV Healthcare in Singapore, where she was VP Commercial, Head Asia Pacific region. She is a medical doctor with broad leadership experience across commercial and medical roles. She has a proven track record of developing high performing teams and an extensive specialty experience within the pharmaceutical industry including in dermatology, immuno-inflammation and rare diseases. She has held several leadership positions internationally in Europe, Asia and Latin America.
“Monica Shaw’s experience in biologics, dermatology and specialty pharma will help us to be successful in our move to launch innovative treatments and become a global leader in medical dermatology. Her combination of global experience, great leadership skills and clinical background will contribute significantly to reach our ambitions,” said Catherine Mazzacco, President and CEO of LEO Pharma.
Nathalie Joannes will join LEO Pharma as Executive Vice President, Legal and Compliance and General Counsel from September 1, 2020. She joins LEO Pharma from Roquette Freres’ headquarters in Paris, where she has been Group General Counsel. During Joannes’ long-standing career as general counsel in the life-sciences and pharmaceutical industries, she successfully built international teams in legal, risk management and compliance in publicly traded and privately owned, global companies. She holds a Juris Doctor Degree from Université de Liège, a Master of Law from University of Pennsylvania Law School and has been admitted to the New York Bar.
“Nathalie Joannes has a proven track record in counseling global companies and her global pharma and life-science industry experience will be of great value for LEO Pharma on its way to become a leading provider of innovative medicines. She is a highly experienced lawyer and builder of strong international teams, which will help us immensely,” said Mazzacco.
Effective July 1, 2020, Guillaume Clemént, currently Executive Vice President, Region Europe+, will assume responsibility for Region International and the thrombosis business, after having successfully led Region Europe+ in the last four years.
Official bios
Monica Shaw
Dr. Monica Shaw, M.D., is a medical doctor with broad leadership experience across commercial and medical roles. She has a proven track record of developing high performing teams to deliver business performance and successful drug development. Monica Shaw has extensive specialty experience within the pharma industry working within dermatology, immuno-inflammation, HIV, neurology and oncology. She has held several leadership positions in the global pharma industry located in i.e. Europe, Asia and Latin America.
Monica Shaw earned an M.D. M.A. and is a Member of the Royal College of Physicians.
Employment History
VP Commercial Head Asia Pacific region, GSK/ViiV Healthcare
2018 to current
General Manager, GlaxoSmithKline
2016 – 2018
VP Global Franchise Medical Head for Specialty, GlaxoSmithKline
2014 – 2016
UK Chief Scientific Officer, Novartis
2013 – 2014
Global Therapy Area Director for Clinical Development and Business Development, Norgine
2011 – 2013
Global Clinical Director ADHD, Shire
2009 – 2011
Nathalie Joannes
Nathalie Joannes holds a Juris Doctor Degree from Université de Liège, a Master of Law from University of Pennsylvania Law School and has been admitted to the New York Bar since 1987. During her long-standing career as general counsel in the chemical and pharmaceutical industries, she successfully built international teams and guided listed pharma companies through the legal aspects of mergers & acquisitions, partnerships, high-risk litigations, anti-trust investigations, corporate governance and compliance.
Employment History
Group General Counsel, Roquette Frères
2016 to current
EVP and Group General Counsel, IPSEN
2011 – 2015
SVP and Chief European Counsel, Genzyme
2008 – 2011
General Counsel International, Cardinal Health
2007 – 2008
Group General Counsel, Serono International
2001 – 2007
Contacts
Henrik Kyndlev
+45 3140 6180
HDTDK@LEO-Pharma.com
Images
About LEO Pharma
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 92 million patients in 130 countries. In 2019, the company generated net sales of DKK 10,805 million. For more information please visit: www.leo-pharma.com
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma Takes Centre Stage With its Largest-Ever Scientific Programme at EADV 202515.9.2025 15:00:00 CEST | Pressemeddelelse
For the second year in a row, LEO Pharma delivers its largest and most ambitious scientific programme ever at the 2025 European Academy of Dermatology and Venereology (EADV), setting a new standard by presenting an unprecedented volume of scientific content for the company, with 5 late-breaking presentations and 24 regular abstracts.1-29 LEO Pharma’s scientific programme at EADV 2025 spans multiple dermatological indications, mirroring the company’s strong commitment to addressing both the most prevalent chronic skin diseases and hard-to-treat conditions.1-29 Highlights from EADV 2025 includes exciting phase 3 data in biologic injectables as well as foam and cream formulations, illustrating the breadth of therapeutic approaches represented in LEO Pharma’s medical dermatology portfolio.1-29
LEO Pharma delivers 7% revenue growth at CER in H1 2025 and achieves key milestones enabling future growth18.8.2025 12:00:00 CEST | Pressemeddelelse
Ballerup, Denmark, 18 August, 2025 - In H1 2025, LEO Pharma delivered robust growth and significantly improved profitability, enabling an increase to the financial outlook for sales growth and adjusted EBITDA margin in 2025 towards the upper-end of previously communicated expectations. In July, the FDA approval of Anzupgo® and partnership with Boehringer Ingelheim for SPEVIGO®, marked major strategic milestones demonstrating LEO Pharma’s commitment to advancing innovation in dermatology. Highlights LEO Pharma’s revenue increased by 6% year-on-year to DKK 6,789 million, and by 7% at constant exchange rates (CER) entirely driven by organic growth. The revenue growth was led by North America (+28% at CER), with Europe (+1% at CER) and Rest of World (+4% at CER) also contributing to the overall growth. Revenue from the Dermatology portfolio grew by 8% (CER) year-on-year, driven by the Strategic brands Adtralza®/Adbry® and Anzupgo®, which combined had a revenue increase of 51% (CER). Sales
LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.23.7.2025 22:30:00 CEST | Pressemeddelelse
ANZUPGO® (delgocitinib) cream now becomes the first and only FDA-approved treatment specifically approved for the treatment of adults living with moderate-to-severe chronic hand eczema (CHE) in the U.S.1 CHE affects approximately one in ten adults worldwide, yet previously, there has been no specific treatment FDA-approved for those living with the disease.2,3 The approval represents an important milestone for LEO Pharma’s expanding presence in the U.S. as it broadens its portfolio of dermatology treatments to address unmet needs.
Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab)14.7.2025 13:00:00 CEST | Pressemeddelelse
Partnership will accelerate and broaden access to treatment for more patients with generalized pustular psoriasis (GPP), a rare and devastating skin condition LEO Pharma’s six decades of dermatology expertise and Boehringer’s global track record in bringing SPEVIGO® to over 40 countries will be combined to ensure continuous patient support Boehringer Ingelheim and LEO Pharma will closely cooperate to ensure a smooth transition of all operations
LEO Pharma Announces Positive 16-Week Interim Results for ADHAND Trial for Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis on the Hands who are Candidates for Systemic Therapy9.7.2025 13:00:00 CEST | Pressemeddelelse
ADHAND is a phase 3b placebo-controlled clinical trial evaluating the efficacy and safety of tralokinumab in adult patients living with moderate-to-severe atopic dermatitis on the hands who are candidates for systemic therapy.1 The 16-week interim results of the ADHAND trial met the primary and all key secondary endpoints, showing statistically significant results compared to placebo. This analysis assessed outcomes up to Week 16, but the trial will continue through Week 32, with final results expected by the end of the year.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom